Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093292 | 0.95 | SIGMAR1 (0.57) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL8500204 | 0.93 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL2097303 | 0.93 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL791697 | 0.89 | CYP1A2 (0.55) | SIGMAR1CYP1A2CYP2A6HDAC1HRH3 | |
| SCHEMBL4625658 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL6298407 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL21954858 | 0.84 | TSHR (0.49) | CYP1A2CYP2C8HTR2A | |
| SCHEMBL29853788 | 0.84 | TSHR (0.49) | CYP1A2CYP2C8HTR2A | |
| SCHEMBL16594736 | 0.82 | KDM4E (0.49) | SIGMAR1CYP1A2CYP2A6HRH3HTR2A | |
| SCHEMBL16594922 | 0.82 | KDM4E (0.49) | SIGMAR1CYP1A2CYP2A6HRH3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2012062996-A1 | DERIVATIVES OF 6-AMINO-6-DEOXYGLUCOSAMINE AND USE OF SAME AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2012-05-18 | — | — | WO | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1250332-A1 | INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION | Abbott Laboratories (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001044223-A1 | INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION | ABBOTT LABORATORIES (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | SIGMAR1 3134/4885CYP1A2 2708/4885CYP2A6 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.